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ABSTRACT
P u r p o s e ;  W e  e v a l u a t e d  t h e  u r o d y n a m i c  a n d  c l i n i c a l  e f f e c t s  o f  t e r a z o s i n  i n  p a t i e n t s  w i t h  
s y m p t o m a t i c  b e n i g n  p r o s t a t i c  h y p e r p l a s i a  ( B P H ) .
M a t e r i a l s  a n d  M e t h o d s :  A  t o t a l  o f  4 5  p a t i e n t s  w h o  p a r t i c i p a t e d  i n  a  n m l t i c e n t e r  t r i a l  w a s  
e v a l u a t e d  w i t h  u r o d y n a m i c  p r e s s u r e - f l o w  s t u d i e s  b e f o r e  a n d  a f t e r  2 6  w e e k s  o f  t r e a t m e n t .
R e s u l t s :  M a x i m u m  f l o w  r a t e  a n d  s y m p t o m  s c o r e  i m p r o v e d  s i g n i f i c a n t l y  i n  2 2  p a t i e n t s  w i t h  a n d  
1 1  w i t h o u t  b l a d d e r  o u t l e t  o b s t r u c t i o n  w h o  c o m p l e t e d  2 6  w e e k s  o f  t r e a t m e n t .  I n  p a t i e n t s  w i t h  
b l a d d e r  o u t l e t  o b s t r u c t i o n  t h e  c o n d i t i o n  w a s  s i g n i f i c a n t l y  r e d u c e d  a n d  i n  p a t i e n t s  w i t h o u t  
o b s t r u c t i o n ,  s i g n i f i c a n t  u r o d y n a m i c  c h a n g e s  c o u l d  n o t  b e  d e t e c t e d .
C o n c l u s i o n s :  T e r a z o s i n  t r e a t m e n t  r e s u l t s  i n  s y m p t o m a t i c  r e l i e f  a n d  i m p r o v e d  u r i n a r y  f l o w  i n  
p a t i e n t s  w i t h  a n d  w i t h o u t  b l a d d e r  o u t l e t  o b s t r u c t i o n ,  a n d  i n  s i g n i f i c a n t  i m p r o v e m e n t  i n  p a t i e n t s  
w i t h  u r o d y n a m i c  a l l y  p r o v e d  o b s t r u c t i o n .
Key Words: prostate, prostatic hyperplasia, urodynamics, adrenergic alpha receptor blockaders
Benign prostatic hyperplasia (BPH) develops in almost 
half of all men older than 50 years.1 Traditionally, the first 
choice of treatment in patients with symptomatic BPH was 
prostatectomy. The incidence of postoperative complica­
tions (5 to 10%),2 treatment failures (25 %)3 and reoperations 
(10%)4 after prostatectomy, and the knowledge that this con­
dition is not inevitably of a rapidly progressive, deteriorating 
nature have led to the development of new safe and effective 
nonoperative treatments.
In 1976 Caine et al demonstrated that phenoxybenzamine, 
a nonselective a 1-2 blocker, could be effective for the treat­
ment of patients with BPH.5 However, the widespread use of 
this compound was limited by the appearance of a signifi­
cantly high incidence of side effects. With the introduction of 
prazosin, an a l selective blocking agent, similar efficacy but 
fewer side effects were shown.6 Since then, several reports 
have documented the beneficial effects of new selective a l  
blockers in patients with symptomatic BPH.7-8
Terazosin is a long-acting a l selective blocking agent 
that was originally used in the treatment of patients with 
hypertension. The effects of terazosin on symptom scores 
and urinary flow rates in patients with symptomatic BPH 
have been documented in several studies.7,9 The reported 
incidence of side effects is low. Side effects are related to 
the a adrenergic blocking effect and include headache, 
dizziness and asthenia. An advantage of terazosin over 
prazosin is that the longer half-life allows for a once daily 
dosage regimen. Terazosin administered at bedtime mini­
mizes the percentage of patients who experience tiredness 
and dizziness during the day, and increases the percentage 
of responders who have severe nocturia.10 Besides evalua­
tion of symptom score and free urine flow, we examined at
1 center the outcome of pressure-flow studies on the treat­
ment of patients with symptomatic BPH who participated 
in a multicenter international randomized withdrawal 
trial designed to evaluate the long-term safety and efficacy 
of terazosin.
MATERIALS AND METHODS
We report the urodynamic and clinical results of terazosin 
therapy in patients with symptomatic BPH who were in­
cluded in a multicenter international randomized with­
drawal trial at our center in Nijmegen. The results of the 
multicenter trial have been reported previously.9 Symptom­
atic BPH was diagnosed in all patients by medical history, 
physical examination (including digital palpation and ultra­
sonographic examination of the prostate), blood analysis, 
baseline International Prostate Symptom Score (I-PSS) of 12 
or more and a maximum free urinary flow rate of 5 to 15 ml. 
per second inclusive, with a total voided volume of 100 ml. or 
more and a post-void residual volume of less than 300 ml. 
Prostatic volume was calculated using the planimetric 
method on an ultrasound scanner with a multiplane 3-di­
mensional rectal transducer. All patients were considered 
neurologically normal based on history, symptoms and phys­
ical examination (no motor, sensory or reflex deficits).
After symptomatic BPH was diagnosed clinically patients 
began treatment with terazosin administered at bedtime and 
increasing to a maximum dose of 10 mg. per day at 6 weeks. 
During part 1 of the study urodynamic pressure-flow tests 
before and after 26 weeks of treatment with terazosin were 
used to evaluate urodynamic changes. Urinary sediment and 
culture were negative at the time of pressure-flow studies. To 
control patient compliance, plasma terazosin levels were meas­
ured at 26 weeks of treatment. According to the study proto­
col, at 26 weeks of therapy patients were categorized based 
on the symptomatic response and free flow result into those 
who did and did not respond to treatment. Responders, that 
is patients with an I-PSS improvement of 30% or more from 
baseline and an increase in maximum free urinary flow rate 
of 10% or more from baseline, were then randomly allocated 
to maintain the dosage of terazosin or to receive placebo. The 
patients then entered part 2 of the study (24 weeks), during 
which they were seen at 8-week intervals to receive the 
double-blind medication and to record symptoms and free 
urinary flow rates.
The pressure-flow studies were performed with an 8F 
transurethral lumen catheter with an intravesical microtip 
pressure sensor for bladder pressure recordings. Abdominal
Accepted for publication October 6 , 1995.
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pressure was recorded intrarectally with an 8F microtip sen­
sor catheter. Before cystometry the bladder was emptied 
through the lumen of a transurethral catheter to quantify 
residual volume after free uroflowmetry. Thereafter, the 
bladder was filled with water at 20C with a filling speed of 50 
mL per minute with the patient supine. In consideration of 
the micturition diary, free uroflowmetry and residual urine 
volume, care was taken to fill the bladder until the maximum 
bladder capacity was reached and filling was stopped when 
the patient expressed a strong urge to void. To provide an 
objective and precise grading of obstruction, pressure-flow 
graphs were fitted with a passive urethral resistance relation 
curve at the lowest pressure part of the graph.11 Minimal 
detrusor pressure during micturition and computed theoret­
ical cross-sectional urethral area were calculated automati­
cally based on the manually adjusted passive urethral resis­
tance relation curves.11 The detrusor pressure at maximum 
flow during the urodynamic investigation was recorded.
Correction for flow artifacts was performed when neces­
sary. The parameter urethral resistance relation was deter­
mined by fitting the pressure-flow plot at the point of maxi­
mum flow (at detrusor pressure at maximum flow). Urethral 
resistance relation was computed to classify patients on a 
continuous, 1-parameter scale of obstruction.12 The linear 
passive urethral resistance relation was determined by draw­
ing a straight line between the 2 points on the pressure-flow 
curve that corresponded to the detrusor pressure at maxi­
mum flow and the minimal detrusor pressure during void­
ing.13 The position of this straight line defined the outlet 
condition in a simple way and afforded classification of the 
severity of outlet obstruction. Urodynamic parameters ana­
lyzed were maximum free urinary flow rate, free voided vol­
ume ? maximum flow during urodynamic investigation, detru­
sor pressure at maximum flow, minimal detrusor pressure 
during voiding, theoretical cross-sectional urethral area and 
urethral resistance relation for all patients, for those without 
obstruction (linear passive urethral resistance relation less 
than 3) and for those with obstruction (linear passive ure­
thral resistance relation 3 or more).14 We investigated the 
possible differences in treatment effects between the obstruc­
tion and no obstruction groups using previously defined re­
sponse criteria for each urodynamic parameter and symptom 
score (table 1). We also examined possible differences in 
initial urodynamic parameters between the patients who did 
and did not respond to treatment according to the definition 
of the study protocol. Statistical analysis was performed us­
ing the Wilcoxon matched pairs signed rank test and the 
Wilcoxon rank sum W test for analysis of numerical data, and 
the chi-square test for comparison of categorical data.
RESULTS
A total of 45 patients (mean age 64.2 years, range 50 to 76) 
began treatment with terazosin increasing to a maximum 
dose of 10 mg. per day at 6 weeks. The ultrasonographic ally 
detected prostatic volume ranged from 20 to 94 cc (mean 44). 
A total of 30 patients (64%), including 3 unable to void during 
the pressure-flow investigation, was categorized as having 
obstruction and 12, including the 3 unable to void during the 
initial investigation, stopped treatment during part 1 of the 
study due to dizziness in 2, asthenia in 4, cardiac arrhythmia 
in 1, dyspnea in 2, poor compliance in 2 and progressive 
complaints with a urinary tract infection in 1. Of the patients 
33, including 22 (67%) with obstruction, underwent pressure- 
flow studies before and after 26 weeks of terazosin treatment. 
The initial I-PSS total symptom score and initial detrusor 
pressure at maximum flow, labeled according to the reason 
for dropping out before week 26 and response status accord­
ing to the definition of the study protocol at 26 weeks of 
treatment, are plotted for each individual in figure 1. Pa­
tients who dropped out of the study because of toxicity had
Table 1 . Percentages o f urodynamic and symptomatic responders 
in the obstruction and no obstruction groups after 26 weeks of
terazosin treatm ent
% % No 
Obstruction Obstruction P * 
_____________________________________(22 pts.) (11 pts.) Va,ue
Maximum free flow rate increase:
10% or More 59
50% or More 32
Free voided vol. increase of 50 ml. 23 
or more
Minimal urethral opening pres- 55
sure decrease of 10 cm. water 
or more
Maximum urodynamic flow rate 36
increase of 2 ml./sec. or more 
Detrusor pressure at maximum 64
flow decrease of 10 cm. water 
or more
Computed urethral area during 36
voiding increase of 1 mm,2 or 
more
Computed urethral resistance de- 55 
crease of 10 cm. water or more 
Total I-PSS symptom score de­
crease:
30% or More 67
50% or More 57
Responders according to study 41
protocolt
:l! Chi-square test.
f Increase in maximum free flow rate of 10% or more and decrease in total 
I-PSS of 30% or more after 26 weeks of treatment.
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Fig. 1. Scatterplot of detrusor pressure at maximum flow in cm. 
water (y axis) and total I-PSS (x axis) for each individual, labeled 
according to reasons for dropping out of study during first 26 weeks 
of treatm ent and response status according to definition of study 
protocol at 26 weeks of treatment. ZJTI, urinary tract infection.
symptomatic and urodynamic values that were heteroge­
neously distributed among those who completed the first 26 
weeks of therapy. Mean urodynamic parameters and symp­
tom scores at baseline for the initial 45 patients, and at 
baseline and after 26 weeks of treatment for 33 patients 
divided in 2 subgroups with and without obstruction are 
shown in table 2. Maximum free urinary flow rate and I-PSS 
symptom score improved significantly in the entire group of 
patients (mean 2.3 ml. per second and 10 points, respectively; 
p = 0.002 and p <0.001, respectively). In the obstruction 
group the mean maximum free urinary flow rate improved by 
1.6 ml. per second, which was not statistically significant (p 
= 0.06). However, mean improvement in maximum flow dur­
ing urodynamic investigation (1.9 ml. per second) was signif­
icant (p = 0.01). In the no obstruction group mean improve­
ment in maximum free urinary flow rate (3.6 ml. per second) 
was statistically significant (p = 0.01) but mean improve-
A *  side*effects
A O UTI
• non-responder 
Ä responder
*
*
A
A,
A
A * A * A
A A * o A
A
A
A A
*
A
A
T "
91
18
45
0.06
0.41
0.18
22 0.09
45 0.61
36 0.14
14 0.27
0 <0.01
100
64
91
0.03
0.72
<0.01
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Table 2. Urodynamic and symptomatic results at baseline for the initial 45 patients, an d  at baseline an d  2 6  weeks after starting
terazosin treatment for 33 patients divided into subgroups o f  22 with and 11 without obstruction
Initial Group 
(45 pts.)
33 Pts. Completing 26 Wks. Terazosin
mi l / ' »  m. i- Obstruction Total Group Obstruction *
(11 pts.) W  ptSj
Maximum free flow rate (ml./sec.):
Baseline 9.1 ± 2.7 9.0 ± 2.8 9.7 ± 2.6 8.6 ± 2.9
Wk. 26 -- 11.3 ± 4.4 13.3 ± 3.8 10.2 ± 4.3
p Value 0.002 0.01 0.06
Free voided vol. (ml.):
Baseline 224 ± 98 203 ± 91 224 ± 129 192 ± 66
Wk. 26 -- 215 ± 111 244 ± 98 200 ±117
p Value 0.97 0.66 0.76
Residual urine (ml.):
Baseline 62 ± 87 67 ± 99 22 ± 24 76 ± 111
Wk. 26 -- 60 ± 81 55 ± 56 66 ± 90
p Value 0.82 0.12 0.36
Minimal urethral opening pressure (cm. water):
Baseline 37.2 ± 22.0 38.7 ± 24.2 20.3 ± 9.5 46.3 ± 24.5
Wk. 26 -- 29.5 ± 16.8 23.0 ± 16.0 33.3 ± 16.9
p Value 0.13 0.44 0.04
Maximum urodynamic flow rate (ml./sec.):
Baseline 7.3 ± 3.5 7.1 ± 3.6 9.0 ± 4.2 6.2 ± 2,9
Wk. 26 -- 8.9 ± 5,2 10.6 ± 6,1 8.1 ± 4.6
p Value 0.01 0.32 0.01
Detrusor pressure at maximum flow (cm. water):
Baseline 70.7 ± 32.0 72.7 ± 34.2 43.4 ± 9.2 87.3 ± 32.6
Wk. 26 -- 59.4 ± 28.2 44.6 ± 18.8 66.7 ± 29.5
p Value 0.01 0,79 0.01
Computed urethral area during voiding (mm.2):
Baseline 3.2 ± 3.2 3.2 ± 3.6 3.4 ± 1.7 2.3 ± 0.9
Wk, 26 -- 3,9 ± 2.4 3.7 ± 1.4 3.7 ± 2,5
p Value 0.001 0.50 <0.001
Computed urethral resistance (cm. water):
Baseline 42.1 ± 18.4 43.6 ± 19.6 25.2 ± 6.9 51.9 ± 17.7
Wk. 26 _ 34.2 ± 17.7 24.2 ± 12,4 38.8 ± 18.5
p Value 0.002 0.51 <0.002
Total I-PSS symptom score:
Baseline 19.7 ± 5.5 20.1 ± 5.9 21.1 ± 7.3 19.6 ± 5.3
Wk. 26 - - - 9.7 ± 5.4 8.6 ± 5.4 10.3 ± 5.4
p Value <0.001 0.003 <0.001
Comparison of baseline versus week 26 values (mean plus or minus standard deviation) using the Wilcoxon matched pairs signed rank test.
ment in maximum flow during urodynamic investigation (1,6 
ml. per second) was not (p = 0.32). Symptom scores improved 
significantly in both groups (p <0.001 with and p = 0.003 
without obstruction).
Mean pressure-flow parameters of maximum flow during 
urodynamic investigation, minimal detrusor pressure du­
ring voiding, detrusor pressure at maximum flow, theoretical 
cross-sectional urethral area and urethral resistance relation 
in the obstruction group significantly improved after 26 
weeks of terazosin treatment. In the patients without ob-
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F ig. 2. Improvement in urethral resistance relation (URA) in cm. 
water (y axis) and I-PSS symptom score (x axis) plotted for each 
individual patient with and without obstruction who completed 26 
weeks of terazosin therapy.
struction significant changes could not be detected. Figure 2 
shows the improvements in urethral resistance relation and 
I-PSS symptom score plotted for each patient who completed 
26 weeks of therapy. The majority of obstruction patients 
had symptomatic and urodynamic improvement after 26 
weeks of terazosin treatment. Symptomatic improvement in 
the group without obstruction was comparable with that 
of the group with obstruction. The changes in urethral resis­
tance relation in the no obstruction group were not great and 
the majority were within physiological variability.
Table 1 shows the number of responders according to the 
study protocol, and the number of responders for each uro­
dynamic parameter and symptom score in both groups. Of 22 
patients with and 11 without obstruction 13 (59%) and 10 
(91%), respectively, had a 10% or greater increase in maxi­
mum free urinary flow rate (p = 0.06). In comparison, 7 of 22 
patients (32%) with and 2 of 11 (18%) without obstruction 
had greater differences in maximum free urinary flow rate 
(50% or more) (p = 0.41). A total of 12 of 22 patients (55%) 
with and none without obstruction had a decrease in urethral 
resistance relation of 10 cm. water or more, and this differ­
ence was statistically significant (p <0.01). The number of 
patients classified as responders according to the study pro­
tocol definition was significantly greater in the group without 
obstruction (p = 0.006). Passive urethral resistance relation 
curves based on mean urodynamic values for both groups at 
baseline and after 26 weeks of treatment are shown in figure
3.
Table 3 provides an overview of the mean initial urody­
namic parameters between the groups who did and did not 
respond to treatment. The mean urodynamic parameters of 
theoretical cross-sectional urethral area, urethral resistance
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A Flow (m!/sec} B Flow (ml/sac)
F ig . 3. Passive urethral resistance relation curves based on m ean urodynamic values for obstruction (A) and no obstruction (B ) groups at 
baseline (1 ) and after 26 weeks of treatm ent (2). + , m ean detrusor pressure at maximum flow. P detr , deti'usor pressure.
Table 3. Initial clinical and urodynamic values for pa tien ts  with  
and without response according to the study protocol definition
_ _ _
----------------------------------------------------------- p
Response No Response Vahiet 
(19 pts.)* (14 pts.)
Maximum free flow rate (ml./sec.) 10.2 ± 3,6 8.0 n  i | m 2.4 0.11
Free voided vol. (ml.) 216 -4* 105 197 ± 67 0.86
Residual vol. (ml.) 46 + 68 95 ± 124 0.20
Minimal urethral opening pressure 34.0 25.0 44.5 ± 22.9 0.05
(cm. water)
Maximum urodynamic flow rate (ml./sec.) 8.6 ± 4.0 5.2 1.0 0.006
Detrusor pressure at maximum flow 66.5 ± 37,1 81.0 ± 29.0 0.05
(cm. water)
Computed urethral area during voiding 4.2 ± 4.8 2.0 4- 0.7 0.03
(mm.2)
Computed urethral resistance (cm. water) 36.3 -+* 19.4 52.9 ± 16.2 0.002
Linear passive urethral resistance relation 2.6 1.5 3.9 I£ 1,0 0.004
Total I-PSS symptom score 21.2 6.5 18.6 ± 4,9 0.31
* Increase in maximum free flow rate of 10% or more and decrease in total 
I-PSS of 30% or more after 26 weeks of treatment.
f  Wilcoxon rank sum W test.
relation and linear passive urethral resistance relation were 
significantly different, indicating that patients without ob­
struction were more likely to respond to treatment according 
to the study protocol definition compared to those with ob­
struction (fig. 1).
After the first 26 weeks of treatment 19 of 33 patients were 
categorized as responders according to the protocol definition 
and were randomized to receive further treatment. For the 
next 24 weeks 5 obstruction and 4 no obstruction responders 
were randomized to maintain the dosage of terazosin, and 4 
obstruction and 6 no obstruction responders received placebo. 
During part 2 of the protocol 3 patients (1 randomized to 
continue terazosin and 2 receiving placebo) interrupted 
treatment because of progressive complaints. Table 4 shows 
the mean values of maximum free urinary flow rate and 
symptom scores for all patients, as well as for those with 
versus without obstruction and randomized to receive pla­
cebo versus terazosin. During part 2 of the study symptom 
scores deteriorated significantly in the placebo group (p = 
0.02), whereas the improved symptom scores in the terazosin 
group were maintained. A mean terazosin level of 114 ng./ml. 
(range 66 to 187) 26 weeks after beginning therapy showed 
good drug compliance in the study population.
The most frequent treatment related side effects were mild 
headache, dizziness and asthenia. Usually, these side effects
were mild and transient. Six patients stopped treatment 
because of such events. In 1 patient treatment was stopped 
because of progressive complaints after 8 weeks of therapy 
that later were found to be related to a culture proved uri­
nary tract infection. Dyspnea and cardiac arrhythmia were 
other reasons for cessation of treatment but these events 
were not considered to be treatment related.
DISCUSSION
Traditionally, an important objective method to assess the 
effect of a new treatment modality in BPH is urinary flow 
measurement. However, there is great variability in consec­
utive measurements of uroflo wine try. Golomb et al evaluated 
the variability of urinary flow in 32 patients with BPH and 
16 healthy volunteers.15 The variability between consecutive 
maximum flow rates was observed in the BPH group from at 
least 1 standard deviation (5.7 ml. per second) in 28 of 32 
patients to at least 2 standard deviations in 15 of 32. Fur­
thermore, on voiding nomograms the highest recorded max­
imum flow rate was greater than the 2 standard deviation 
plot, while the lowest maximum flow rate was less than the
2 standard deviation plot. It is obvious that this great vari­
ability in measurements of uroflowmetry has a marked neg­
ative impact on the power of statistical tests to assess a 
difference in the intra-individual and interindividual urinary 
flow rate. Furthermore, it largely increases sample size re­
quirements to achieve statistical power. These difficulties 
were already recognized in 1982 by Drach et al, who sug­
gested to adjust the maximum urinary flow rate for varying 
age and volume voided.16 Presently, it is accepted that the 
poor urinary stream in 20 to 25% of patients with symptom­
atic BPH is due to a hypo active detrusor muscle.3 This fact 
emphasizes the relative importance of urinary flow meas­
urement in assessing the effect of a treatment modality in 
patients with symptomatic BPH, especially in small groups.
During the international consultation on BPH in 1993 it 
was advised that, if obstruction is the end point of the study, 
pressure-flow studies before and after treatment should be 
used in the evaluation of new therapies.17 Pressure-flow 
studies enable us to investigate the relationship between 
subjective efficacy of treatment and objective voiding param­
eters. Moreover, the use of pressure-flow studies may help to 
select patients for a given treatment and, therefore, dropout 
and over treatment percentages may decrease considerably.
Patients may be selected for a given treatment using the 
linear passive urethral resistance relation diagram, a classi-
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fication of the degree of bladder outlet obstruction.14 This 
diagram is divided into 7 bands, labeled 0 to 6, representing 
increasing severity of obstruction. Bands 0 and 1 represent 
an unobstructed, bands 2 and 3 a minimally obstructed, and 
bands 4 to 6 an increasingly severe obstructed outlet condi­
tion.13*14 In patients with a linear passive urethral resistance 
relation of 0 or 1, categorized as without obstruction, the poor 
urinary stream i s caused by a hypo active detrusor muscle, 
These patients have little chance to benefit from transure­
thral resection of the prostate.14 Pharmacotherapy in this 
group must have been used frequently but to our knowledge 
efficacy results in this specific group of patients have not 
been reported, probably because they were not identified by 
pressure-flow analyses.
Between the unobstructed and obviously obstructed 
groups, with poor urinary streams and high intravesical 
pressures noted by a linear passive urethral resistance rela­
tion of 4 or more, there is a gray zone of patients with a linear 
passive urethral resistance relation of 2 and 3 who have 
minimal bladder outlet obstruction. We divided the gray zone 
of patients with minimal obstruction into 2 groups; 1) those 
with a linear passive urethral resistance relation of 2 or less 
were classified as without obstruction and 2) those with a 
linear passive urethral resistance relation of 3 or more were 
classified as with obstruction. With this classification we 
were able to show differences in clinical and urodynamic 
treatment responses between the 2 groups.
In the obstruction group all mean values for maximum 
flow during urodynamic investigation, minimal detrusor 
pressure during voiding, detrusor pressure at maximum 
flow, theoretical cross-sectional urethral area and urethral 
resistance relation after 26 weeks of terazosin improved 
significantly. From a theoretical viewpoint, the mecha­
nism of voiding using an a l  adrenergic blockader is 
changed towards better outlet distensibility during voiding 
and, thus, becomes more efficient. The first effect of a 
decrease in outlet obstruction is presumably a change in 
the balance of bladder outlet and detrusor contraction 
towards a lower pressure micturition with improved effi­
cacy, Theoretically, the increase in maximum urinary flow 
rate might not be as high as may be expected, which may 
be partly attributed to a decrease in voiding detrusor pres­
sure. More efficient voiding can also be shown by lower 
post-void residual volumes but this could not be demon­
strated by our patients who had a low mean residual 
volume of 62 ml. with a high standard deviation of 87 ml. 
In our study more efficient micturition after terazosin is 
clearly evident in the obstruction group in which urody­
namic parameters improved significantly, particularly the 
improvement in maximum free urinary flow rate. A signif­
icant change in theoretical cross-sectional urethral area 
together with a significant change in minimal detrusor 
pressure during voiding indicates that terazosin has 
relaxed the bladder outlet so that more efficient voiding 
can occur.
The patients without obstruction showed no significant 
urodynamic changes. Ironically, the group with the highest 
percentage of patients showing slight improvements in free 
flow and symptoms had no urodynamic obstruction. When we 
evaluated greater improvements in free flow and symptoms, 
there was no significant difference between the percentage of 
patients in either group (table 1), which demonstrates that in 
our patients without obstruction statistically significant im­
provements in symptoms or free flow were not confirmed by 
significant improvements in urodynamic variables. This find­
ing suggests that the way we analyze efficacy in the majority 
of pharmacotherapy studies for BPH (that is improvements 
in symptoms and maximum free urinary flow rate) is not 
entirely representative of the urodynamic mechanism of ac­
tion. Moreover, the results of urodynamic studies in men who 
received treatment for BPH depend on the percentage of
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included patients who actually have obstruction. In other 
words, a high percentage of patients without obstimction will 
mask the urodynamic effect that is clearly shown in those 
with obstruction. Tammela and Kontturi reported a mean 
decrease in detrusor pressure at maximum flow of 39 cm. 
water after finasteride treatment for 6 months and a mean 
increase in detrusor pressure at maximum flow of 3 cm. 
water in the placebo group, indicating a significant urody­
namic response to treatment.18 Such a large urodynamic 
response can only be expected in patients with severe outlet 
obstruction. Considering the high mean detrusor pressure at 
maximum flow values in the study of Tammela and Kontturi 
(mean detrusor pressure at maximum flow 120 cm. water), 
the majority of the included patients had severe bladder 
outlet obstruction. The urodynamic response in a study eval­
uating the efficacy of doxazosin, an a l  selective blocker, 
although significantly better compared to placebo, was slight 
(improvement in detrusor pressure at maximum flow 5 cm. 
water),8 Mean detrusor pressure at maximum flow in the 
doxazosin study was 78 cm. water, indicating that a higher 
percentage had less severe obstruction compared to the study 
of Tammela and Kontturi. These findings imply that mean 
urodynamic differences between therapy groups must be re­
garded critically.
The maximum flow during urodynamic investigation is 
lower than the maximum free urinary flow rate and this 
difference is systematic, probably due to the transurethral 
catheter and the different type of investigation. The large 
variability in consecutive measurements in urinary flow meas­
urement is also illustrated in our study. In all patients sig­
nificant improvements in maximum flow during urodynamic 
investigation (1.8 ml. per second) and maximum free urinary 
flow rate (2.3 ml. per second) could be detected, which is in 
accordance with the results of the multicenter trial in which 
239 patients completing the first 26 weeks of therapy had a 
significant improvement in maximum free urinary flow rate 
of 3.2 ml. per second.9 The differences in our study were 
statistically significant only for maximum free urinary flow 
rate in the no obstruction group and maximum flow during 
urodynamic investigation in the obstruction group. In the no 
obstruction group the power to detect a true difference of 2.0 
ml. in maximum flow during urodynamic investigation at a 
significance level a of 0.05 was only 21%. In the obstruction 
group the power to detect a true difference of 2.0 ml. in 
maximum free urinary flow rate at a significance level a of
0.05 was only 64%. Evidently, more patients are needed in 
these subgroups to detect a significant difference in these 
parameters.9
Symptoms obviously responded well to terazosin in both 
groups. This symptomatic response can be differentiated 
from a placebo response, since symptoms during part 2 of this 
study deteriorated significantly in the placebo group, 
whereas the improved symptom score at week 26 in the 
terazosin group was maintained until the end of the study. In 
our study terazosin resulted in significant symptomatic relief 
and significantly improved urinary flow in the majority of 
patients. Terazosin also resulted in improved efficiency of 
micturition and a significant decrease in bladder outlet ob­
struction in the majority of patients with urodynamically 
proved obstruction. As indicated in the multicenter trial9 and 
our study (figs. 1 and 2), few patients do not benefit symp­
tomatically or uro dynamically from terazosin treatment. To 
date laboratory studies have indicated that in the human 
prostate the relative expression of a le adrenergic receptor 
subtypes is predominant,19 A large inter in dividual variation 
of ale expression in BPH specimens could explain why not all 
men react favorably to treatment with a l  selective blocking 
agents.20 Future laboratory studies should be directed to­
wards the search for more prostate specific a l receptor sub- 
types, which would allow development of new a 1-subtype
selective blocking agents resulting in increased therapeutic 
efficacy and fewer side effects.
We have shown that a stratified analysis, based on urody­
namic classification of bladder outlet obstruction, provides 
meaningful insight into the working mechanism of terazosin 
in patients with symptomatic BPH. We also have shown that 
significantly more patients without obstruction, in whom 
no significant urodynamic changes could be detected, had 
slight improvements in maximum free urinary flow rate and 
symptom score compared to those with obstruction, which 
demonstrates that in pharmacotherapy studies that include 
many patients without obstruction clinical response to treat­
ment is not necessarily identical to urodynamic response.
Further prospective clinical investigations in patients clas­
sified according to the grade of bladder outlet obstruction are 
necessary to provide the still needed information on the role 
of bladder outlet obstruction in the evaluation of pharmaco­
logical therapy, and the capability of urodynamic and clinical 
parameters to predict a favorable response to new treat­
ments. Only then can the treatment of symptomatic BPH be 
individualized according to the pathophysiology, complaints 
and expectations of the patient.
CONCLUSIONS
Terazosin results in significant symptomatic relief and 
improved urinary flow in patients with and without bladder 
outlet obstruction. Terazosin also results in improved effi­
ciency of micturition and significantly decreased bladder out­
let obstruction in patients with urodynamically proved ob­
struction.
Hanny Derks-Boes collected the clinical data and Lianne 
M. Damen provided nursing care.
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